Mylan Slumps in After-Hours Trading on Generic Advair Update
Down goes Mylan.

Pounded. 

Mylan NV (MYL) said Wednesday, June 13, that the U.S. Food and Drug Administration "has identified minor deficiencies" that the agency will relay in a letter later this month regarding Mylan's application for a generic version of  GlaxoSmithKline plc's (GSK) asthma drug Advair.

The FDA will issue a complete response letter, which indicates that an application is not yet ready for approval, on June 27.

Shares of Mylan fell 4.3% to $39.90 in after-hours trading. GlaxoSmithKline's American Depository Receipts were up 2.5% to $42.15.

"Because our Abbreviated New Drug Application has received a priority designation, our approval could be received prior to the standard 90-day time period following the date of our response to the Complete Response Letter," Mylan said.

More from Markets

Rewind: Jim Cramer on the Market Selloff, Macy's, Constellation and Canopy

Rewind: Jim Cramer on the Market Selloff, Macy's, Constellation and Canopy

Loncar China BioPharma ETF Makes Nasdaq Debut

Loncar China BioPharma ETF Makes Nasdaq Debut

Stocks Close Lower But Trim Losses With Late Rebound

Stocks Close Lower But Trim Losses With Late Rebound

China Set to 'Weaponize' Yuan to Fight Trump's Trade War: Report

China Set to 'Weaponize' Yuan to Fight Trump's Trade War: Report

Jim Cramer on Canopy Growth's New $4 Billion Stake From Constellation Brands

Jim Cramer on Canopy Growth's New $4 Billion Stake From Constellation Brands